This page shows the latest Brintellix news and features for those working in and with pharma, biotech and healthcare.
EMA backs Lundbeck's Brintellix in depression. Drug recommended for approval to treat major depressive episodes in adults. ... In the latest round of EU drug recommendations, Lundbeck won backing for the use of Brintellix in the treatment of adult
Lundbeck buoyed by Brintellix approval in US. FDA gives green light for to Cipralex/Lexapro successor in depression. ... Lundbeck was celebrating yesterday after the FDA approved its new antidepressant Brintellix, a successor to the big-selling
Lundbeck and Takeda submit depression drug for US approval. Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex. ... Lundbeck's plans to find a replacement for its big-selling antidepressant Lexapro/Cipralex continue
Brexipiprazole is one of a trio of new drugs Lundbeck and alliance partner Otsuka are relying on to drive growth in the coming years, alongside recently launched antidepressant Brintellix ( vortioxetine) and
Desmoteplase is one of a stable of new products Lundbeck is bringing through development to handle the loss of patent protection for antidepressant Lexapro ( escitalopram), along with next-generation antidepressant Brintellix ( vortioxetine),
antidepressant Brintellix ( vortioxetine) and Abilify Maintena ( aripiprazole) to build sales momentum.
More from news
Approximately 3 fully matching, plus 14 partially matching documents found.